Charlie Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual intensive outpatient mental health treatment for adolescents and young adults, Bozeman MT, raised $55M+. Addresses crisis-level care gaps via virtual IOP.
About
Charlie Health is a Bozeman, Montana-based virtual mental health company founded in 2020 that provides intensive outpatient program (IOP) care for adolescents, young adults, and families experiencing mental health crises. The company has raised over $55 million and targets the significant care gap between inpatient psychiatric hospitalization and standard outpatient therapy — a level of care that has historically been difficult to access, particularly outside major urban centers.\n\nCharlie Health's virtual IOP model delivers nine or more hours of structured group and individual therapy per week through a telehealth platform, allowing clients to receive high-intensity care from home while maintaining school or work routines. The clinical approach combines dialectical behavior therapy (DBT), cognitive behavioral therapy (CBT), and trauma-informed care, with treatment teams including licensed therapists, psychiatrists, and care coordinators. Programs are designed for adolescents aged 11 to 17 and young adults aged 18 to 26 presenting with depression, anxiety, trauma, self-harm, and suicidality.\n\nThe company accepts insurance from most major carriers, a deliberate strategic choice to reach underserved populations who cannot afford self-pay intensive treatment. Charlie Health's telehealth delivery model gives it geographic reach into rural and suburban communities where brick-and-mortar IOPs are scarce, positioning the company as an infrastructure solution for the adolescent mental health crisis that intensified during the COVID-19 pandemic.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.